ArticlesEffectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data
Introduction
Toxoplasma gondii is a common parasitic infection acquired by ingestion of oocysts excreted by cats and contaminating soil or water, or by eating tissue cysts that remain viable in undercooked meat of infected animals.1, 2 Mother-to-child transmission of the parasite occurs only when infection is acquired for the first time during pregnancy. The risk of transmission rises steeply with gestational age at maternal infection.3 Overall, about a third of infected mothers give birth to an infant with toxoplasmosis.3, 4 Most children with congenital toxoplasmosis are developmentally normal5 but up to 4% die or have evidence of permanent neurological damage or bilateral visual impairment during the first years of life.6, 7
Toxoplasma infection in pregnancy is usually asymptomatic and can only be detected by serological testing. Prenatal testing for toxoplasmosis is routinely offered in many European countries so that infected mothers can be treated with antibiotics to reduce the risk of mother-to-child transmission and, if fetal infection has occurred, to reduce impairment in the child.8 No consensus exists about the most effective screening strategy or the best type of treatment. Uncertainty about the benefits of prenatal treatment9 and concerns about adverse treatment effects and the infrastructure and costs needed to implement prenatal screening have led to diverse policies including no screening, neonatal screening6, 10, 11 and prenatal screening with monthly or 3-monthly re-testing schedules.4, 8, 12, 13 In countries where prenatal screening is done, recommendations for treatment can differ. In most centres, including those in France, spiramycin is prescribed immediately after diagnosis of maternal infection and changed to a pyrimethamine-sulphonamide combination if fetal infection is diagnosed or if infection is acquired in late pregnancy.4 By contrast, in Austria, mothers are initially treated with pyrimethamine-sulphonamide (after 15 weeks of gestation), and changed to spiramycin if fetal diagnosis is negative.4
So far, two systematic reviews have evaluated the effect of prenatal treatment on mother-to-child transmission.9, 14 No randomised controlled trials were found and we know of no subsequent trial. Meta-analysis of the effect of prenatal treatment was not possible in these reviews because of differences between studies in analytical methods and the way aggregate data were presented. However, new observational data have been published since then: three analyses of retrospective cohort studies12, 13, 15, 16 and the results of a large prospective multicentre cohort study.4, 7 None of these studies reported a significant effect of treatment on mother-to-child transmission but none could exclude clinically important effects. The findings for the effect of prenatal treatment on the risk of clinical manifestations of congenital toxoplasmosis (intracranial and ocular lesions) have been inconsistent.7, 12, 13, 16
Our aim was to estimate the effects of timing and different types of prenatal treatment on the risk of congenital toxoplasmosis and its clinical manifestations during infancy, with a systematic review using individual patients' data to undertake a meta-analysis.
Section snippets
Study selection
Any cohort study of women identified during pregnancy by universal screening for T gondii infection was eligible for inclusion if the following data had been recorded. For the analysis of mother-to-child transmission: sample dates for the last negative and first positive specific antibody tests; date prenatal treatment was started; date of birth or last menstrual period; and congenital infection status on the basis of specific antibody tests beyond 11 months postnatal age. Exact dates for
Results
We found no randomised controlled trials in our search. 26 observational cohorts were included in the review, including a total of 1745 infected mothers and 691 infected liveborn infants. Three cohorts from the same study12 had relevant data but the investigators declined to participate (96 mothers, 43 infected infants). Investigators for four further studies,23, 24, 25, 26 accounting for 288 mothers and 49 infected infants, did not respond (figure 1). Studies of prenatal screening varied from
Discussion
We found weak evidence for an increased risk of mother-to-child transmission the later prenatal treatment was started after maternal seroconversion. This result might be due to a true protective effect of early treatment, or to confounding caused by selective treatment of mothers at high risk of fetal infection whose infection was diagnosed late—ie, outside the standard monthly or 3-monthly re-testing schedule. We found no evidence that prenatal treatment significantly reduced the risk of
References (34)
- et al.
Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling
Lancet
(1999) - et al.
Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year
Am J Obstet Gynecol
(1999) Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease
Am J Ophthalmol
(2003)- et al.
Direct genotyping of animal and human isolates of Toxoplasma gondii from Colombia (South America)
Acta Tropica
(2006) - et al.
Sources of toxoplasma infection in pregnant women: European multicentre case-control study
BMJ
(2000) - et al.
Toxoplasmosis
Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii
BJOG
(2003)- et al.
Determinants of response to a parent questionnaire about development and behaviour in 3 year olds: European multicentre study of congenital toxoplasmosis
BMC Pediatr
(2005) - et al.
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection
N Engl J Med
(1994) - et al.
Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres
Acta Paediatrica
(2005)
Prevention of congenital toxoplasmosis in Europe [in German]
Schweiz Med Wochenschr Suppl
Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy
BMJ
High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study
Int J Epidemiol
Low incidence of toxoplasma infection during pregnancy and in newborns in Sweden
Epidemiol Infect
Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol
Epidemiol Infect
Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem?
J Med Screen
Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France
Int J Epidemiol
Cited by (384)
Inactivation of Toxoplasma gondii in dry sausage and processed pork, and quantification of the pathogen in pig tissues prior to production
2023, Food and Waterborne ParasitologyCongenital Toxoplasmosis, Syphilis, Malaria, and Tuberculosis
2023, Avery's Diseases of the NewbornIs the incidence of congenital toxoplasmosis declining?
2023, Trends in ParasitologyNewer Updates in Pediatric Intracranial Infection
2023, Seminars in RoentgenologyAssessment of the clinical benefits of prenatal screening for toxoplasmosis in southern Taiwan
2022, Taiwanese Journal of Obstetrics and Gynecology
- ‡
Members listed at end of report